AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25142196 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medication (ADM) alone
Number of subjects: 452
Study 23363666 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily bathing in chlorhexidine gluconate (CHG) 2%
Number of subjects: 4947
Study 23363666 — intervention group
Group type: COMPARATOR
Intervention: Standard bathing practices
Number of subjects: 4947
Study 20092709 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg intravenous drip, once every 12 hours)
Number of subjects: 152
Study 20092709 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg intravenous injection, once every 8 hours)
Number of subjects: 152
Study 20092709 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Erythromycin and Metoclopramide)
Number of subjects: 152
Study 17932089 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-CAT (Cognitive Adaptation Training focused on community adaptation including grooming, care of living quarters, leisure skills, social and role performance, and medication adherence)
Number of subjects: 95
Study 17932089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharm-CAT (Cognitive Adaptation Training focused only on medication and appointment adherence)
Number of subjects: 95
Study 17932089 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 95
Study 21703078 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC) brands used for restorations (specific brands not detailed)
Number of subjects: 804
Study 21703078 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrestoration meal of 'hard consistency'
Number of subjects: 804
Study 21703078 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer cement brands
Number of subjects: 804
Study 16220400 — intervention group
Group type: EXPERIMENTAL
Intervention: 22‐day fractionation schedule (2.5 Gy to 55 Gy, 4x/week, n = 65)
Number of subjects: 129
Study 16220400 — intervention group
Group type: COMPARATOR
Intervention: 28-day conventional fractionation schedule (2.0 Gy to 55 Gy, 5x/week, n = 64)
Number of subjects: 129
Study 11891037 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc pleurodesis with patient rotation for 1 hour
Number of subjects: 20
Study 11891037 — intervention group
Group type: COMPARATOR
Intervention: Talc pleurodesis with patients remaining in stable supine position
Number of subjects: 20
Study 11891037 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc dispersion after rotation
Number of subjects: 20
Study 11891037 — intervention group
Group type: COMPARATOR
Intervention: Talc dispersion without rotation
Number of subjects: 20
Study 11891037 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintigraphic imaging after 1 hour
Number of subjects: 20
Study 11477828 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS‐ST93‐1 plaster
Number of subjects: 163
Study 11477828 — intervention group
Group type: COMPARATOR
Intervention: TTS‐Scopolamine plaster
Number of subjects: 163
Study 11477828 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose plaster)
Number of subjects: 163
Study 7648374 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg/d
Number of subjects: 20
Study 7648374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2670634 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day nimesulide
Number of subjects: 40
Study 2670634 — intervention group
Group type: COMPARATOR
Intervention: 500 mg/day naproxen
Number of subjects: 40
Study 13003 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible plastic cannula
Number of subjects: 1100
Study 13003 — intervention group
Group type: COMPARATOR
Intervention: Nonflexible plastic cannula
Number of subjects: 1100
Study 11319723 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary cholesterol intake of up to approximately 800 mg/day
Number of subjects: 65
Study 11319723 — intervention group
Group type: COMPARATOR
Intervention: Insulin-resistant women
Number of subjects: 65
Study 11319723 — intervention group
Group type: COMPARATOR
Intervention: Insulin-sensitive women
Number of subjects: 65
Study 31208472 — intervention group
Group type: EXPERIMENTAL
Intervention: iHIVARNA-01 (HIVACAT T-cell immunogen (HTI)-TriMix)
Number of subjects: 100
Study 31208472 — intervention group
Group type: COMPARATOR
Intervention: TriMix
Number of subjects: 100
Study 31208472 — intervention group
Group type: COMPARATOR
Intervention: Water for injection (WFI)
Number of subjects: 100
Study 31208472 — intervention group
Group type: EXPERIMENTAL
Intervention: iHIVARNA-01
Number of subjects: 100
Study 31208472 — intervention group
Group type: COMPARATOR
Intervention: WFI
Number of subjects: 100
Study 28914724 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic walking
Number of subjects: 159
Study 28914724 — intervention group
Group type: COMPARATOR
Intervention: Nonaerobic stretching and toning
Number of subjects: 159
Study 26999823 — intervention group
Group type: COMPARATOR
Intervention: Standard web-based intervention
Number of subjects: 69
Study 26999823 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Number of subjects: 69
Study 25376417 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion program
Number of subjects: 0
Study 23359970 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Fujia Mixture (FFM), 3 times daily for one month as 1 therapeutic course, in addition to Levothyroxine Sodium Tablet (LST) as routine treatment.
Number of subjects: 60
Study 23359970 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine Sodium Tablet (LST) as routine treatment.
Number of subjects: 60
Study 19852964 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin
Number of subjects: 320
Study 19852964 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin
Number of subjects: 320
Study 19852964 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin (genotype 1/4)
Number of subjects: 320
Study 19852964 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin (genotype 1/4)
Number of subjects: 320
Study 19852964 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin (genotype 2/3)
Number of subjects: 320
Study 19852964 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin (genotype 2/3)
Number of subjects: 320
Study 19852964 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin (without cirrhosis)
Number of subjects: 320
Study 19852964 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin (without cirrhosis)
Number of subjects: 320
Study 19852964 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin (HCV RNA >500,000 IU/mL)
Number of subjects: 320
Study 19852964 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin (HCV RNA >500,000 IU/mL)
Number of subjects: 320
Study 19852964 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin (baseline HCV RNA <or=500,000 IU/mL)
Number of subjects: 320
Study 19852964 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin (baseline HCV RNA <or=500,000 IU/mL)
Number of subjects: 320
Study 19852964 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin (cirrhosis)
Number of subjects: 320
Study 19852964 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin (cirrhosis)
Number of subjects: 320
Study 18066962 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombophilia screening protocol including hereditary thrombophilic disorders, antiphospholipid antibodies, and hyperhomocysteinemia.
Number of subjects: 216
Study 18066962 — intervention group
Group type: EXPERIMENTAL
Intervention: Hereditary thrombophilia
Number of subjects: 216
Study 18066962 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 216
Study 15906077 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepburn heart and lung exerciser (HHALE) training for 6 weeks
Number of subjects: 18
Study 15906077 — intervention group
Group type: COMPARATOR
Intervention: Control group (ceased training after 6 weeks)
Number of subjects: 18
Study 12581422 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage‐colony stimulating factor alone
Number of subjects: 0
Study 12581422 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic fibroblast growth factor alone
Number of subjects: 0
Study 12581422 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage‐colony stimulating factor and basic fibroblast growth factor given in sequence
Number of subjects: 0
Study 12581422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10583355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular bupivacaine
Number of subjects: 107
Study 10583355 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular fentanyl
Number of subjects: 107
Study 8708963 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) technique using expanded polytetrafluoroethylene (ePTFE) barriers
Number of subjects: 16
Study 8708963 — intervention group
Group type: COMPARATOR
Intervention: Conventional periodontal surgery
Number of subjects: 16
Study 8708963 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted system
Number of subjects: 16
Study 1931532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (therapeutic dosage, serum levels of 10-20 micrograms/ml) for two months
Number of subjects: 24
Study 1931532 — intervention group
Group type: COMPARATOR
Intervention: Placebo for two months
Number of subjects: 24
Study 7145250 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.1 mg
Number of subjects: 10
Study 7145250 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg
Number of subjects: 10
Study 7145250 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.4 mg
Number of subjects: 10
Study 7145250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30819457 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week STP-PreK
Number of subjects: 45
Study 30819457 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week STP-PreK
Number of subjects: 45
Study 30819457 — intervention group
Group type: COMPARATOR
Intervention: school year behavioral consultation (SC)
Number of subjects: 45
Study 29500534 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-case surgery (DCS) group
Number of subjects: 124
Study 29500534 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospitalization (CH) group
Number of subjects: 124
Study 26056021 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 24
Study 26056021 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive exercise only (RE)
Number of subjects: 24
Study 26056021 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 24
Study 26056021 — intervention group
Group type: COMPARATOR
Intervention: Long-term recovery (RVE vs control)
Number of subjects: 24
Study 24495633 — intervention group
Group type: EXPERIMENTAL
Intervention: The COACH Program plus usual care
Number of subjects: 0
Study 24495633 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 22369708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet and reminder (A)
Number of subjects: 242
Study 22369708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet only (B)
Number of subjects: 242
Study 22369708 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 242
Study 21126295 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (all-in-one self-etch adhesive; 3M ESPE) after water cleansing
Number of subjects: 75
Study 21126295 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (self-etch primer system; Kuraray America) after water cleansing
Number of subjects: 75
Study 21126295 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Easy Bond (all-in-one self-etch adhesive; 3M ESPE)
Number of subjects: 75
Study 21126295 — intervention group
Group type: COMPARATOR
Intervention: Saliva contamination without cleansing
Number of subjects: 75
Study 21126295 — intervention group
Group type: COMPARATOR
Intervention: Saliva and cleansing with water
Number of subjects: 75
Study 21126295 — intervention group
Group type: COMPARATOR
Intervention: Saliva and cleansing with 2% chlorhexidine
Number of subjects: 75
Study 21126295 — intervention group
Group type: COMPARATOR
Intervention: Saliva and cleansing with 5% sodium hypochlorite
Number of subjects: 75
Study 18260945 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 70
Study 18260945 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 70
Study 15821962 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization in 142 patients
Number of subjects: 253
Study 15821962 — intervention group
Group type: COMPARATOR
Intervention: Medically treated in 111 patients
Number of subjects: 253
Study 12117084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium 4% nasal solution
Number of subjects: 1150
Study 12117084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1150
Study 9863701 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-back task
Number of subjects: 7
Study 9863701 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-back task
Number of subjects: 7
Study 9863701 — intervention group
Group type: COMPARATOR
Intervention: 0-back task
Number of subjects: 7
Study 8549085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-impedance spectroscopy
Number of subjects: 29
Study 8549085 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-frequency bio-impedance analysis
Number of subjects: 29
Study 2793699 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercaloric diet with 53% of calories as carbohydrate (CB)
Number of subjects: 16
Study 2793699 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercaloric diet with 55% of calories as fat (FB)
Number of subjects: 16
Study 2793699 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose plus electrolytes (D5W) infusion for 48 hours
Number of subjects: 16
Study 669542 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzopyrone preparation (Venalot)
Number of subjects: 295
Study 669542 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyphenbutazone
Number of subjects: 295
Study 669542 — intervention group
Group type: COMPARATOR
Intervention: Control group (analgesic only)
Number of subjects: 295
Study 31823314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices received clinical quality measure (CQM) reports at least quarterly, hosted an on-site visit and 2 webinars, and sent clinician/staff representatives to a 'best practice' meeting.
Number of subjects: 107094
Study 31823314 — intervention group
Group type: COMPARATOR
Intervention: Control practices received CQM reports at least quarterly.
Number of subjects: 107094
Study 30636632 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive spinal anesthesia using 27-gauge pen type fine spinal needles (experimental group, n = 110)
Number of subjects: 202
Study 30636632 — intervention group
Group type: COMPARATOR
Intervention: 22-gauge traditional spinal needles (control group, n = 92)
Number of subjects: 202
Study 27831502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab and trastuzumab with chemotherapy (paclitaxel, epirubicin, cyclophosphamide)
Number of subjects: 396
Study 26410801 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal massage (10‐minute perineal massage with glycerol four times during the first stage and once during the second stage of labor)
Number of subjects: 284
Study 26410801 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 284
Study 23880548 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare model
Number of subjects: 345
Study 23880548 — intervention group
Group type: EXPERIMENTAL
Intervention: VGNW model
Number of subjects: 345
Study 23880548 — intervention group
Group type: EXPERIMENTAL
Intervention: BAR model
Number of subjects: 345
Study 20943783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet treatment for up to 4.5 years
Number of subjects: 81
Study 19364963 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 0
Study 19364963 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 0
Study 17400953 — intervention group
Group type: COMPARATOR
Intervention: Copenhagen (moist snuff)
Number of subjects: 10
Study 17400953 — intervention group
Group type: EXPERIMENTAL
Intervention: Commit (medicinal nicotine lozenge)
Number of subjects: 10
Study 17400953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ariva (PREP)
Number of subjects: 10
Study 17400953 — intervention group
Group type: EXPERIMENTAL
Intervention: Revel (PREP)
Number of subjects: 10
Study 17400953 — intervention group
Group type: EXPERIMENTAL
Intervention: Stonewall (PREP)
Number of subjects: 10
Study 15213063 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 27
Study 15213063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 11231439 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 81
Study 11231439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 10447840 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape feedback and lecture methods for teaching alcohol brief intervention skills
Number of subjects: 0
Study 10447840 — intervention group
Group type: COMPARATOR
Intervention: Lecture and demonstration about the principles and practice of brief alcohol intervention
Number of subjects: 0
Study 7589046 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 12
Study 7589046 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard 20 mg
Number of subjects: 12
Study 7589046 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined atenolol 100 mg and nifedipine retard 20 mg
Number of subjects: 12
Study 7589046 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5 mg (active control)
Number of subjects: 12
Study 7589046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2273526 — intervention group
Group type: EXPERIMENTAL
Intervention: Refusals skills training program
Number of subjects: 78
Study 2273526 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 7468987 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (higher dose)
Number of subjects: 28
Study 7468987 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (lower dose)
Number of subjects: 28
Study 31274119 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (4 doses of Norfloxacin 400mg, twice a day for two days)
Number of subjects: 251
Study 31274119 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 251
Study 27898215 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive drainage (daily drainage)
Number of subjects: 149
Study 27898215 — intervention group
Group type: COMPARATOR
Intervention: Standard drainage (every other day drainage)
Number of subjects: 149
Study 26003169 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme chromosomal instability (CIN) defined as MCD4 group tumours.
Number of subjects: 1173
Study 26003169 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme chromosomal instability (CIN) in ER-negative/HER2-negative cancers.
Number of subjects: 1173
Study 23218591 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (15 min prior to radiation)
Number of subjects: 200
Study 23218591 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 min rest prior to radiation)
Number of subjects: 200
Study 22072355 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative immune-enhancing formula for malnourished patients (DS)
Number of subjects: 50
Study 22072355 — intervention group
Group type: COMPARATOR
Intervention: Pre-surgical dietetic guidance and intravenous fluids for malnourished patients (DNS)
Number of subjects: 50
Study 22072355 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative nutritional support (DS)
Number of subjects: 50
Study 19698938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) with medication
Number of subjects: 76
Study 19698938 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT) without medication
Number of subjects: 76
Study 17198061 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 18
Study 15099320 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tretinoin peel
Number of subjects: 10
Study 15099320 — intervention group
Group type: COMPARATOR
Intervention: 70% glycolic acid
Number of subjects: 10
Study 11445484 — intervention group
Group type: EXPERIMENTAL
Intervention: Infertile men (n = 66)
Number of subjects: 76
Study 11445484 — intervention group
Group type: COMPARATOR
Intervention: Fertile men (n = 10)
Number of subjects: 76
Study 11352879 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged antiplatelet therapy (6 months of clopidogrel and aspirin)
Number of subjects: 120
Study 11352879 — intervention group
Group type: COMPARATOR
Intervention: Active gamma‐radiation treatment (1 month of antiplatelet therapy)
Number of subjects: 120
Study 11352879 — intervention group
Group type: COMPARATOR
Intervention: Placebo historical control group (1 month of antiplatelet therapy)
Number of subjects: 120
Study 9248985 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg)
Number of subjects: 30
Study 9248985 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 8491318 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing of skin flaps to underlying muscle
Number of subjects: 39
Study 8491318 — intervention group
Group type: COMPARATOR
Intervention: Conventional skin closure
Number of subjects: 39
Study 3622314 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release isosorbide 5-mononitrate 60 mg once daily
Number of subjects: 136
Study 3622314 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release isosorbide 60 mg once daily
Number of subjects: 136